These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 3388295)

  • 1. Patients with prolonged bleeding time of undefined etiology, and their response to desmopressin.
    Kim HC; Salva K; Fallot PL; Karp GI; Eisele J; Matts L; Heller I; Saidi P
    Thromb Haemost; 1988 Apr; 59(2):221-4. PubMed ID: 3388295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Desmopressin in the treatment of hemorrhagic diathesis].
    Haar D; Hasselbalch HC
    Ugeskr Laeger; 1995 Nov; 157(48):6713-5. PubMed ID: 8540136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Desmopressin: a nontransfusional hemostatic agent.
    Mannucci PM
    Annu Rev Med; 1990; 41():55-64. PubMed ID: 2184748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of desmopressin effects on haemostasis in children with congenital bleeding disorders.
    Hanebutt FL; Rolf N; Loesel A; Kuhlisch E; Siegert G; Knoefler R
    Haemophilia; 2008 May; 14(3):524-30. PubMed ID: 18284449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1-Desamino-8-D-arginine vasopressin (DDAVP) infusion in type IIB von Willebrand's disease: shortening of bleeding time and induction of a variable pseudothrombocytopenia.
    Casonato A; Sartori MT; de Marco L; Girolami A
    Thromb Haemost; 1990 Aug; 64(1):117-20. PubMed ID: 2274916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1-Deamino-8-d-arginine vasopressin (DDAVP): a potential new treatment for the bleeding diathesis of acute renal failure.
    Watson AJ; Keogh JA
    Pharmatherapeutica; 1984; 3(9):618-22. PubMed ID: 6728864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of platelet dysfunction and response to DDAVP in patients with congenital platelet function defects. A double-blind placebo-controlled trial.
    Rao AK; Ghosh S; Sun L; Yang X; Disa J; Pickens P; Polansky M
    Thromb Haemost; 1995 Oct; 74(4):1071-8. PubMed ID: 8560416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Utility of desmopressin in 4 cases of thrombocytopathies associated with giant platelets].
    Martínez-Murillo C; Quintana-González S; Ambriz-Fernández R; Arzate-Hernández G; Gutiérrez-Romero M; Gaminio-Gómez E
    Rev Invest Clin; 1997; 49(4):281-6. PubMed ID: 9707993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo effects of desmopressin on platelet function.
    Balduini CL; Noris P; Belletti S; Spedini P; Gamba G
    Haematologica; 1999 Oct; 84(10):891-6. PubMed ID: 10509036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous desmopressin (DDAVP) shortens the prolonged bleeding time in patients with liver cirrhosis.
    Cattaneo M; Tenconi PM; Alberca I; Garcia VV; Mannucci PM
    Thromb Haemost; 1990 Nov; 64(3):358-60. PubMed ID: 2096487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study on mechanisms of a haemostatic effect of 1 deamino-8-D-arginine vasopressin (desmopressin) in uraemic patients.
    Malyszko J; Pietraszek M; Buczko W; Mysliwiec M
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(2):319-24. PubMed ID: 1697836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1-Desamino-8-arginine-vasopressin corrects the hemostatic defects in type 2B von Willebrand's disease.
    McKeown LP; Connaghan G; Wilson O; Hansmann K; Merryman P; Gralnick HR
    Am J Hematol; 1996 Feb; 51(2):158-63. PubMed ID: 8579058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Desmopressin (DDAVP) in bleeding disorders of childhood.
    Sutor AH
    Semin Thromb Hemost; 1998; 24(6):555-66. PubMed ID: 10066151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hemostatic control in platelet dysfunction and abnormality by DDAVP].
    Mito M; Higuchi W; Fuse I; Hattori A; Shibata A
    Nihon Rinsho; 1992 Feb; 50(2):355-9. PubMed ID: 1613990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laboratory response to intranasal desmopressin in women with menorrhagia and platelet dysfunction.
    Rose SS; Faiz A; Miller CH; Saidi P; Philipp CS
    Haemophilia; 2008 May; 14(3):571-8. PubMed ID: 18312366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Thrombocytic alpha-delta-storage-pool-disease: shortening of bleeding time after infusion of 1-desamino-8-D-arginine vasopressin].
    Kosch A; Kehrel B; Nowak-Göttl U; Häberle J; Jürgens H
    Klin Padiatr; 1999; 211(4):198-200. PubMed ID: 10472549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shortening of bleeding time by 1-deamino-8-arginine vasopressin (DDAVP) in the absence of platelet von Willebrand factor in Gray platelet syndrome.
    Pfueller SL; Howard MA; White JG; Menon C; Berry EW
    Thromb Haemost; 1987 Dec; 58(4):1060-3. PubMed ID: 3502198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemostatic and hemodynamic effects of vasopressin analogue DDAVP in patients with cirrhosis.
    López P; Otaso JC; Alvarez D; Rojter S; Podestá A; Albornoz L; Terg R; Romero G; Mastai R
    Acta Gastroenterol Latinoam; 1997; 27(2):59-62. PubMed ID: 9339235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.